Allison Bratzel
Stock Analyst at Piper Sandler
(1.96)
# 2,824
Out of 4,829 analysts
37
Total ratings
50%
Success rate
-0.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $140 → $115 | $36.02 | +219.27% | 1 | Mar 17, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $4 → $6 | $2.42 | +148.45% | 1 | Mar 14, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $30 → $23 | $1.18 | +1,849.15% | 1 | Mar 11, 2025 | |
| ENGN enGene Holdings | Initiates: Overweight | $26 | $2.99 | +769.57% | 1 | Feb 18, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $620 → $725 | $558.90 | +29.72% | 13 | Jan 7, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $12 → $22 | $21.53 | +2.18% | 2 | Nov 14, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $23 | $18.66 | +23.26% | 2 | Nov 14, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $65 → $62 | $33.51 | +85.02% | 1 | Nov 14, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $28 → $42 | $32.37 | +29.75% | 3 | Oct 15, 2024 | |
| ROIV Roivant Sciences | Maintains: Overweight | $20 → $22 | $10.96 | +100.82% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.32 | +204.18% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $2.87 | +598.08% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $2.06 | +870.87% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $44 | $7.94 | +454.51% | 1 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $60.49 | +65.32% | 2 | Feb 8, 2023 |
Ultragenyx Pharmaceutical
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $36.02
Upside: +219.27%
Akebia Therapeutics
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $2.42
Upside: +148.45%
Inozyme Pharma
Mar 11, 2025
Maintains: Overweight
Price Target: $30 → $23
Current: $1.18
Upside: +1,849.15%
enGene Holdings
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $2.99
Upside: +769.57%
argenx SE
Jan 7, 2025
Maintains: Overweight
Price Target: $620 → $725
Current: $558.90
Upside: +29.72%
Travere Therapeutics
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $21.53
Upside: +2.18%
Rigel Pharmaceuticals
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $18.66
Upside: +23.26%
Ionis Pharmaceuticals
Nov 14, 2024
Maintains: Overweight
Price Target: $65 → $62
Current: $33.51
Upside: +85.02%
Scholar Rock Holding
Oct 15, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $32.37
Upside: +29.75%
Roivant Sciences
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $10.96
Upside: +100.82%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.32
Upside: +204.18%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $2.87
Upside: +598.08%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $2.06
Upside: +870.87%
Apr 17, 2023
Assumes: Overweight
Price Target: $44
Current: $7.94
Upside: +454.51%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $60.49
Upside: +65.32%